Filed in archive
Corporate and Industrial News
by ruth on December 19, 2005
In an effort to outbid Dutch start-up Crucell NV which also earlier announced an offer to acquire Berna through an all-share exchange, Novartis plans to offer to pay up in cash.
Switzerland's SonntagsZeitung said that Novartis could offer as much as 16 francs per share for the vaccine maker.
Novartis's offer would be in cash, the newspaper said, providing an advantage over Crucell's all-share offer, the value of which depends on the price of shares in the Dutch firm.
Shares in Crucell have since fallen, however, and the bid is now worth closer to 14 francs per Berna share, giving a total value for the firm of 530 million francs.
Asidef rom Chiron and Berna, Novartis is also one of the pharma giants who expressed interest in taking over third biggest biotech company, Serono.
Sources: Novartis Media Release, Reuters
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/12568
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for Will Novartis Outbid Crucell for Berna Biotech?:
|
Rating: 8.33 out of 3 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
